Fabiola Almeida García

Fabiola Almeida García

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Alina Rodríguez MallonAlina Rodríguez Mallon
Alina Rodríguez Mallon
LGLuis Javier Gonzalez
Luis Javier Gonzalez
Pedro Enrique Encinosa GuzmánPedro Enrique Encinosa Guzmán
Pedro Enrique Encinosa Guzmán
Gervasio Henrique BecharaGervasio Henrique Bechara
Gervasio Henrique Bechara
Gustavo SanchesGustavo Sanches
Gustavo Sanches
MEMario Pablo Estrada
Mario Pablo Estrada
A synthetic 20 amino acid peptide of the ribosomal protein P0 from ticks, when conjugated to keyhole limpet hemocyanin from Megathura crenulata and used as an immunogen against Rhipicephalus microplus and Rhipicephalus sanguineus s.l. species, has shown efficacies of around 90%. There is also experimental evidence of a high efficacy of this conjugate against Amblyomma mixtum and Ixodes ricinus species, which suggest that this antigen could be a good broad-spectrum anti-tick vaccine candidate. In this study, the P0 peptide (pP0) was chemically conjugated to Bm86 as a carrier protein. SDS-PAGE analysis of this conjugate demonstrated that it is highly heterogeneous in size, carrying from 1 to 18 molecules of pP0 per molecule of Bm86. Forty-nine out of the 54 lysine residues and the N-terminal end of Bm86 were found partially linked to pP0 by using LC-MS/MS analysis and the combination of four different softwares. Several post-translational modifications of Bm86 protein were also identified by mass spectrometry. High immunogenicity and efficacy were achieved when dogs and cattle were vaccinated with the pP0–Bm86 conjugate and challenged with R. sanguineus s.l. and R. microplus, respectively. These results encourage the development of this antigen with promising possibilities as an anti-tick vaccine.
1

27 February 2024 in Journal of Natural Products
Verified
Journal Article
Closed access
FGFabiola Almeida García
Fabiola Almeida García
TFTalia Frómeta Fuentes
Talia Frómeta Fuentes
IPIsel Pascual
Isel Pascual
RBRoberto Alonso Bosch
Roberto Alonso Bosch
ABAndrés E. Brunetti
Andrés E. Brunetti
Norberto Peporine LopesNorberto Peporine Lopes
Norberto Peporine Lopes

30 December 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
IPIsel Pascual
Isel Pascual
LMLaura Rivera Méndez
Laura Rivera Méndez
FGFabiola Almeida García
Fabiola Almeida García
MVMario Ernesto Valdés-Tresanco
Mario Ernesto Valdés-Tresanco
RBRoberto Alonso Bosch
Roberto Alonso Bosch
JCJean-Louis Charli
Jean-Louis Charli

1 January 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
IPIsel Pascual
Isel Pascual
PVPedro A. Valiente
Pedro A. Valiente
MVMario E. Valdés-Tresanco
Mario E. Valdés-Tresanco
YAYarini Arrebola
Yarini Arrebola
FGFabiola Almeida García
Fabiola Almeida García
JCJean-Louis Charli
Jean-Louis Charli

28 April 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
IAIsel Pascual Alonso
Isel Pascual Alonso
FGFabiola Almeida García
Fabiola Almeida García
MVMario S. Valdés-Tresanco
Mario S. Valdés-Tresanco
YSYarini Arrebola Sánchez
Yarini Arrebola Sánchez
Daniel Ojeda-del SolDaniel Ojeda-del Sol
Daniel Ojeda-del Sol
Francesc Xavier AvilesFrancesc Xavier Aviles
Francesc Xavier Aviles
Proteolytic enzymes, also known as peptidases, are critical in all living organisms. Peptidases control the cleavage, activation, turnover, and synthesis of proteins and regulate many biochemical and physiological processes. They are also involved in several pathophysiological processes. Among peptidases, aminopeptidases catalyze the cleavage of the N-terminal amino acids of proteins or peptide substrates. They are distributed in many phyla and play critical roles in physiology and pathophysiology. Many of them are metallopeptidases belonging to the M1 and M17 families, among others. Some, such as M1 aminopeptidases N and A, thyrotropin-releasing hormone-degrading ectoenzyme, and M17 leucyl aminopeptidase, are targets for the development of therapeutic agents for human diseases, including cancer, hypertension, central nervous system disorders, inflammation, immune system disorders, skin pathologies, and infectious diseases, such as malaria. The relevance of aminopeptidases has driven the search and identification of potent and selective inhibitors as major tools to control proteolysis with an impact in biochemistry, biotechnology, and biomedicine. The present contribution focuses on marine invertebrate biodiversity as an important and promising source of inhibitors of metalloaminopeptidases from M1 and M17 families, with foreseen biomedical applications in human diseases. The results reviewed in the present contribution support and encourage further studies with inhibitors isolated from marine invertebrates in different biomedical models associated with the activity of these families of exopeptidases.

2 February 2021 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
TSTatiana Y. Samgina
Tatiana Y. Samgina
MTMaria D. Tolpina
Maria D. Tolpina
ASAlexey K. Surin
Alexey K. Surin
SKSergey V. Kovalev
Sergey V. Kovalev
RBRoberto Alonso Bosch
Roberto Alonso Bosch
Albert T. LebedevAlbert T. Lebedev
Albert T. Lebedev